Agustin Aviles

Agustin Aviles

Auto-generated profile, based on publicly available information

Agustin Aviles

Hematology Department ; Oncology Hospital Medical Center Oncology Research Unit National IMSS Ciudad de Mexico

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in Hematology
Verified
Journal Article
Closed access
AAAgustin Aviles
Agustin Aviles
NNNatividad Neri
Natividad Neri
JFJorge Fernandez-Diez
Jorge Fernandez-Diez
LSLuis Martins da Silva
Luis Martins da Silva
MNMaria-Jesùs Nambo
Maria-Jesùs Nambo
Treatment of refractory/relapsed cutaneous T-cell lymphoma (CTCL) remains controversial, most studies included a few patients with a short follow-up. Previously, we performed two small studies employing interferon alpha 2b (IFN) combined with low doses of methotrexate (MTX) or retinoids. Thus, we conducted an open-label clinical trial to assess the benefit and toxicity of the two mentioned regimens in a large number of patients with a longer follow-up of the treatment of refractory/relapsed CTCL. Three-hundred and seventy-seven patients with refractory/relapsed, pathologically confirmed, CTCL, with advanced stages and at least treated with two previous effective regimens in CTCL, were randomized to receive IFN and low doses of MTX compared with IFN and all trans-retinoid acid during 6 months; if a complete response (CR) was not achieved, treatment was continued until 12 months in both arms. At this time, if patient achieves CR, MTX or retinoid was stopped, and the patient continues to receive IFN until progression disease or toxicity. One-hundred and eight patients received IFN for more than 5 years. Toxicity was minimal and well tolerated, no patients needed to modify the administration of IFN secondary to toxicity. The overall complete response was achieved 80% in both arms. Actuarial curves at 5 years showed that progression-free survival was 60% in the IFN/MTX group and 62% in the IFN/retinoids group (P = 0.8) that were not statistically different and overall survival (OS) rates were 70 and 67%, respectively (P = 0.03). Both present schedules showed good tolerance and an excellent OS at 5 years, which is better than the other, more expensive and toxic, regimens. Considering the indolent course of CTCL, we suggested that those regimens, mentioned in this paper, will be regarded as the standard therapy, for patients of this setting. The use of IFN and retinoids or low dose of cytotoxic drugs will be preferred in patients with refractory/relapse CTCL, because OS is good and toxicity is minimal.

30 August 2015 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAugustine Avilès
Augustine Avilès
Nasal, natural-killer T-cell lymphoma (nasal NKTCL ), is a rare presentation of extranodal lymphoma in North-America and Europe, but in some countries, as China and Korea, it is extremely common: 20 to 46 % of T-cell lymphomas. Some studies, analyzed the incidence in Latin-America, but Mexico, based on political and geographic considerations, was not included in these reports. Thus, we performed a retrospective analysis of the patients diagnosed and treated as nasal, NKTCL, in our institution, that is an academic tertiary national reference hospital. From 1988 to 2014, we diagnosed and treated 14,816 cases of non-Hodgkin’s lymphoma, 10,957 (73%) were of B-cell histology and 3822 (26%) were of T-cell histology. Nasal, NKTCL, was the most frequent of the T-cell histology: 40%. We compare our results with other countries and observed that nasal, NKTCL has a low number of cases in North-America, and some countries in Latin-America, as Argentina, Brazil and Chile, but our number will be similar to Guatemala and Peru, that were similar to China and Korea. We think that this neoplasm has a racial basis, independent of environmental factors.

25 June 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
AAAgustin Avilés
Agustin Avilés
NNNatividad Neri
Natividad Neri
RFRaúl Fernández
Raúl Fernández
JHJudith Huerta-Guzmán
Judith Huerta-Guzmán
MNMaria-Jesus Nambo
Maria-Jesus Nambo

27 December 2017 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAgustin Avilès
Agustin Avilès
MNMaria-Jesus Nambo
Maria-Jesus Nambo
NNNatividad Neri
Natividad Neri
Objetive. To assess maternal and fetal outcome of women who receiving chemotherapy during pregnancy to treat Hodgkin lymphoma(HL) in early stages (IA and IIA), we performed an retrospective analysis of 44 women with HL at early stage, diagnosed and treated between 1988 to 2010, in a tertiary reference cancer center.Methods:We analyze data of HL: clinical characteristics and treatment; and special attention to maternal and fetal complications ; children : physical development, assess scholar performance phsycological, cardiac and neurological function and intellegence tests.Results: Forty-four pregnant women were enrolled. Median age was 29.4 (range 21-37)years; most patients were stage IIA (86%), had mediastinal bulky disease (78%) and > 3 nodal sites involved; thus these patients were recorded to have a not favourable condition. Abortion was refused when proposed. All patients received combined chemotherapy: ABVD) ( adryamicin, bleomycin, vinblastine and dacarbazine), even during first trimester, at standar doses and schedules. Radiotherapy, when necessary was administered after delivery in 39 patients. No obstetrical complications were observed. Delivery ocurred between 31 to 36 weks in 10 patients (22%) and > 37 weeks in 34 cases (77%). Four newborns were low-weight: 2012 (median) (range:1750 -2350) g. No clinical malformations were observed and development of children were normal without evidence of cardiac, neurological damage. Behavior, scholar attendance and intellegence tests were normal. With a median follow-up of 120.4 (range 48-299) months, progression-free survival and overall survival were 93% and 95 %, respectively.Conclusion: Chemotherapy as initial therapy appear to be thes best therapeutic approach in these setting of patients, with a excelent outcome to both: mother and children. If radiotherapy is necessary, could be administered after delivery

1 April 2017 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
AAAgustin Avilès
Agustin Avilès
MNMaria-Jesùs Nambo
Maria-Jesùs Nambo
JHJudith Huerta-Guzmàn
Judith Huerta-Guzmàn
SCSergio Cleto
Sergio Cleto
NNNatividad Neri
Natividad Neri

1 March 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
AAAgustin Avilés
Agustin Avilés
MNM. Jesús Nambo
M. Jesús Nambo
NNNatividad Neri
Natividad Neri